Interleukin-2 is required for NKp30-dependent NK cell cytotoxicity by preferentially regulating NKp30 expression
Authors:
Open Access
- 18 April 2024
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1388018
Abstract
Natural killer (NK) cells are key effectors in cancer immunosurveillance, eliminating a broad spectrum of cancer cells without major histocompatibility complex (MHC) specificity and graft-versus-host diseases (GvHD) risk. The use of allogeneic NK cell therapies from healthy donors has demonstrated favorable clinical efficacies in treating diverse cancers, particularly hematologic malignancies, but it requires cytokines such as IL-2 to primarily support NK cell persistence and expansion. However, the role of IL-2 in the regulation of activating receptors and the function of NK cells expanded for clinical trials is poorly understood and needs clarification for the full engagement of NK cells in cancer immunotherapy. Here, we demonstrated that IL-2 deprivation significantly impaired the cytotoxicity of primary expanded NK cells by preferentially downregulating NKp30 but not NKp46 despite their common adaptor requirement for expression and function. Using NK92 and IL-2-producing NK92MI cells, we observed that NKp30-mediated cytotoxicity against myeloid leukemia cells such as K562 and THP-1 cells expressing B7-H6, a ligand for NKp30, was severely impaired by IL-2 deprivation. Furthermore, IL-2 deficiency-mediated NK cell dysfunction was overcome by the ectopic overexpression of an immunostimulatory NKp30 isoform such as NKp30a or NKp30b. In particular, NKp30a overexpression in NK92 cells improved the clearance of THP-1 cells in vivo without IL-2 supplementation. Collectively, our results highlight the distinct role of IL-2 in the regulation of NKp30 compared to that of NKp46 and suggest NKp30 upregulation, as shown here by ectopic overexpression, as a viable modality to harness NK cells in cancer immunotherapy, possibly in combination with IL-2 immunocytokines.Keywords
This publication has 65 references indexed in Scilit:
- Enhancing adoptive T‐cell therapy with fucoidan‐based IL‐2 delivery microcapsulesBioengineering & Translational Medicine, 2022
- All‐trans retinoic acid induces leukemia resistance to NK cell cytotoxicity by down‐regulating B7‐H6 expression via c‐Myc signalingCancer Communications, 2021
- FcRγ Gene Editing Reprograms Conventional NK Cells to Display Key Features of Adaptive Human NK CellsiScience, 2020
- B7-H6 as an efficient target for T cell-induced cytotoxicity in haematologic malignant cellsInvestigational New Drugs, 2020
- The integrated stress response promotes B7H6 expressionJournal of Molecular Medicine, 2019
- Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor ImmunityCell, 2019
- Donor-Derived Natural Killer Cell Infusion after Human Leukocyte Antigen–Haploidentical Hematopoietic Cell Transplantation in Patients with Refractory Acute LeukemiaTransplantation and Cellular Therapy, 2016
- Inhibition of NKp30‐ and 2B4‐mediated NK cell activation by evolutionary different human and bovine CEACAM1 receptorsEuropean Journal of Immunology, 2015
- Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cellsJournal of Autoimmunity, 2015
- Ultra-low Dose Interleukin-2 Promotes Immune-modulating Function of Regulatory T Cells and Natural Killer Cells in Healthy VolunteersMolecular Therapy, 2014